EOC Pharma Group

Data from LAG-3 trials caused a stir at the 2021 ASCO meeting, with promising clinical data in this third class of checkpoint inhibitor presented by firms such as Regeneron Pharmaceuticals, Inc. , M

AADi Bioscience, Inc. ’s Fyarro (nab-sirolimus) is the first drug approved by the US Food and Drug Administration for locally advanced unresectable or metastatic malignant perivascular epithelioid cel

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda Teams With KSQ On Cancer Immunot